CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Elekta is a leading human care company, specialising in cancer and brain disorders treatment. Based in Stockholm, Sweden, Elekta offers advanced equipment and software to more than 6,000 hospitals worldwide. The company’s products are divided into the Elekta Neuroscience, Elekta Oncology, Elekta Brachytherapy, and Elekta Software lines. The company has a long history of acquisitions, including deals with Philips Medical Systems, Finland’s Neuromag, IMPAC Medical Systems, CMS, Canada’s Resonant Medical, and Nucletron. Elekta trades on the NASDAQ Stockholm under the EKTA B ticker. Stay tuned to the latest Elekta share price swings with Capital.com.
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024
Read our reviews to find out more about us
Read the feedback from our clients, whatever their experience level.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.